Aethlon Medical, Inc.

Good day and welcome to the Athlon Medical third quarter fiscal 2024 earnings and corporate update. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note today's event is being recorded. I would now like to turn the conference over to Michael Miller with RX communications. Please go ahead.

Thank you operator and good afternoon, everyone. Welcome to Athlon medicals, third quarter fiscal 2024 earnings conference call. My name is Michael Miller with RX communications at 4 15 PM Eastern time today. Athlon Medical released financial results for its third fiscal quarter ended December 31st, 2023. If you have not seen or received Athlon Medical's earnings release, please visit the investors page at www.athlonmedical.com. Following this introduction and the reading of the company's forward-looking statement, Athlon's interim chief executive officer and chief financial officer, James Frakes, and Athlon's chief medical officer, Dr. Steven LaRosa will provide an overview of AFON's strategy and recent developments. Mr. Frakes will then make some brief remarks on AFON's financials. We'll then open up the call for the Q&A session. Before I hand the call over to Mr. Frakes, please note that the news released today and this call contain forward-looking statements within the meaning of the Securities Act of 1933 as amended and the Securities Exchange Act of 1934 as amended. The company cautions you that any statement that is not a statement of historical fact is a forward looking statement. These statements are based on expectations and assumptions as of the date of this conference call. Such forward looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward looking statements. Factors that could cause results to differ materially from those anticipated in forward looking statements can be found under the caption risk factors and the company's annual report on form 10 K the fiscal year ended March 31st, 2023. And the company's most recent report on form 10 Q and the company's other filings with the securities and exchange commission, except as may be required by law, the company does not intend nor does undertake any duty to update this information to reflect future events or circumstances with that. I'll now turn the call over to Mr. James Frakes, Athlon's interim chief executive officer and chief financial officer. Jim.

Thank you, Mike. And I'd like to thank all of you for dialing in. This is Jim Frakes, interim CEO and longtime CFO of Athlon Medical. In October 2023, Athlon received clearance from the Drug Controller General of India, or DCGI, the country's central drug authority, to conduct a phase one safety, feasibility, and dose finding trial of the hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD1 monotherapy treatment, such as Keytruda or Opdivo. The trial is expected to begin following completion of an in vitro binding study of relevant targets and subsequent approval by the respective ethics boards of interested sites in India. In addition to an interested initial site in India, we have three interested sites in Australia that are also awaiting the data from our in vitro binding study. Our in vitro binding study of relevant oncology targets is complex and stands on the cutting edge of extracellular vesicle science. Our goal is to quantify the potential impact of our hemopurifier on plasma from cancer patients who have been treated with anti-PD-1 monotherapy treatment in order to provide preclinical evidence to support our trial design. While our R&D team has started to quantify our internal data, the results to date are inconclusive. Therefore, while our internal team continues to fine-tune their work, in parallel, we have now engaged several third-party laboratories to independently perform assays on the samples. We are also continuing to study the use of our hemopurifier as a treatment against life-threatening viral infections through our COVID-19 trial in India. We have two participating sites for this trial, the Medanta MediCity Hospital and Malana Azad Medical College, or MAMC. One patient has been treated to date. Recently, we have been informed by our contract research organization that a new COVID-19 sub-variant has been detected in India. A COVID-19 trial in India remains open in the event that there are COVID-19 admissions to the intensive care units at our two participating sites. Finally, since being named interim chief executive officer three months ago, I have focused our efforts on our oncology program as well as on reducing our expenses. As previously reported, we disclosed some interesting preclinical proof of concept data of the hemopurifier in organ transplantation. As a result, we do plan to submit one or more articles for publication on our preclinical organ transplantation data. With that, I will now turn the call over to Dr. Steven LaRosa, Athlon's Chief Medical Officer.